Panel Discussion: Setting the Boundaries of What’s Clinically Achievable in RAS Therapy Defining the Realistic Therapeutic Window for Next-Generation Strategies
- How does differential targeting influence tolerability and depth of pathway inhibition, and where do selective versus broader approaches ultimately succeed or fail?
- How should mutant-selective versus wild-type-sparing strategies be balanced to deepen inhibition without breaching tolerability limits, especially when layering multi-agent regimens?
- How can safety-first design principles, PK/PD-guided exposure management, mechanism-based toxicity mitigation, and early integration of safety margins, enable continuous pathway suppression and long-term disease control?